Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.61 |
| ▸ | ESR1 | P03372 | 7/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.52 |
| ▸ | PPARD | Q03181 | 7/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12035621 | 1.00 | HSD17B1 (0.61) | HSD17B1ESR1ESR2PPARDPPARA | |
| SCHEMBL2464209 | 1.00 | HSD17B1 (0.61) | HSD17B1ESR1ESR2PPARDPPARA | |
| SCHEMBL30515129 | 1.00 | HSD17B1 (0.61) | HSD17B1ESR1ESR2PPARDPPARA | |
| SCHEMBL2358440 | 0.92 | HSD17B1 (0.56) | HSD17B1ESR1ESR2PPARDPPARA | |
| SCHEMBL4819783 | 0.92 | HSD17B1 (0.56) | HSD17B1ESR1ESR2PPARDPPARA | |
| SCHEMBL4632528 | 0.92 | HSD17B1 (0.56) | HSD17B1ESR1ESR2PPARDPPARA | |
| SCHEMBL13110353 | 0.91 | ESR1 (0.56) | HSD17B1ESR1ESR2PPARDPPARA | |
| SCHEMBL13424132 | 0.89 | MTNR1A (0.55) | HSD17B1ESR1ESR2PPARDNQO2 | |
| SCHEMBL16077453 | 0.88 | PPARD (0.53) | HSD17B1PPARDPPARAFFAR1 | |
| SCHEMBL13284781 | 0.88 | PPARD (0.53) | HSD17B1PPARDPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | T3D THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| WO-2018102399-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| WO-2018102358-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476742-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| WO-2008054675-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1414809-B1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER CORP (US) | 2008-03-12 | — | — | EP | disclosed |
| CN-1854118-A | Indane acetic acid compound | BAYER PHARMACEUTICALS CORP (US) | 2006-11-01 | — | — | CN | disclosed |
| EP-1578715-A2 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | Bayer Pharmaceuticals Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| CN-1558905-A | Indane acetic acid derivatives, their use as medicaments, intermediates and processes for their preparation | ������˹ҩƷ��˾ | 2004-12-29 | — | — | CN | disclosed |
| WO-2004058174-A2 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | HSD17B1 89/4885ESR1 813/4885ESR2 1219/4885 |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, CHRNA2 | HSD17B1 438/4885ESR1 3103/4885ESR2 2651/4885 |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | HSD17B1 866/4885ESR1 1845/4885ESR2 916/4885 |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | HSD17B1 866/4885ESR1 1845/4885ESR2 916/4885 |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | PPARD, PPARA, PPARG | HSD17B1 104/4885ESR1 1114/4885ESR2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.